WESTBURY, N.Y., Nov. 13,
2013 /PRNewswire/ -- Vasomedical, Inc. ("Vasomedical")
(OTC BB: VASO), a diversified medical technology company
specializing in the design, manufacture and sale of medical devices
for noninvasive cardiology, including EECP® Therapy
systems, the gold standard of ECP therapy, today announced it has
been named to the Deloitte's Technology Fast 500™ for the second
consecutive year, with a ranking of 207 on the 2013 list, up from
443 on the 2012 list.
The Deloitte's Technology Fast 500 List is an annual ranking of
the 500 fastest growing technology, media, telecommunications, life
sciences and clean technology companies in North America. The
ranking is based on percentage annual revenue growth from 2008 to
2012, during which Vasomedical's total annual revenue increased by
501.2 percent.
"Vasomedical's success over the past several years is clearly a
direct result of effective implementation of the strategy the Board
of Directors put into place. This includes diversifying our
business, broadening our product offering and market presence
through development and acquisition, as well as restructuring the
leadership team with individuals with deep industry experience,"
commented Dr. Jun Ma, President and
CEO of Vasomedical, Inc.
"We are pleased to be included on this list of prestigious
companies, and this honor highlights the strides our Company has
made in the right direction. We will continue to implement our
growth strategy in the domestic and international medical
marketplaces and continue to build value for our shareholders."
"The Deloitte's 2013 Technology Fast 500 companies are exemplary
cases of those spurring growth in a tough market through
innovation," said Eric Openshaw,
vice chairman, Deloitte LLP and U.S. technology, media and
telecommunications leader. "This year's list is a who's who
of companies behind the most exciting and innovative products and
services in the technology space. We congratulate the Fast 500
companies and look forward to what they do next."
About Vasomedical
Vasomedical, Inc. is a diversified
medical technology company specializing in the manufacture and sale
of medical devices and in the domestic sale of diagnostic imaging
products. The Company's main proprietary products are
EECP® Therapy systems, the gold standard of ECP
treatment. The Company operates through three wholly owned
subsidiaries: VasoSolutions, Vasomedical Global and VasoHealthcare.
VasoSolutions manages and coordinates the design, manufacture and
sales of EECP® Therapy systems, and other medical equipment
operations; Vasomedical Global operates the Company's China-based subsidiaries; and VasoHealthcare
is the operating subsidiary for the exclusive sales representation
of GE Healthcare diagnostic imaging products in certain market
segments. Additional information is available on the Company's
website at www.vasomedical.com
Forward-Looking Statement
Except for historical
information contained in this release, the matters discussed are
forward-looking statements that involve risks and uncertainties.
When used in this release, words such as "anticipates", "believes",
"could", "estimates", "expects", "may", "plans", "potential" and
"intends" and similar expressions, as they relate to the Company or
its management, identify forward-looking statements. Such
forward-looking statements are based on the beliefs of the
Company's management, as well as assumptions made by and
information currently available to the Company's management. Among
the factors that could cause actual results to differ materially
are the following: the effect of business and economic conditions;
the effect of the dramatic changes taking place in the healthcare
environment; the impact of competitive procedures and products and
their pricing; medical insurance reimbursement policies; unexpected
manufacturing or supplier problems; unforeseen difficulties and
delays in the conduct of clinical trials and other product
development programs; the actions of regulatory authorities and
third-party payers in the United
States and overseas; uncertainties about the acceptance of a
novel therapeutic modality by the medical community; continuation
of the GEHC agreement; and the risk factors reported from time to
time in the Company's SEC reports. The Company undertakes no
obligation to update forward-looking statements as a result of
future events or developments.
Investor Contacts:
Todd
Fromer / Garth Russell
KCSA Strategic Communications
212-896-1215 / 212-896-1250
tfromer@kcsa.com / grussell@kcsa.com
Media Contacts:
Samantha
Wolf / Andrew Herweg
KCSA Strategic Communications
212-896-1220 / 212-896-1273
swolf@kcsa.com / aherweg@kcsa.com
SOURCE Vasomedical, Inc.